What excipients are combined with ruxolitinib in apotex's medication?

What excipients does Apotex combine with ruxolitinib in its tablets?

Apotex manufactures a generic ruxolitinib tablet that contains the same active ingredient as the brand-name drug. The formulation lists microcrystalline cellulose, lactose monohydrate, crospovidone, hydroxypropyl cellulose, magnesium stearate, and colloidal silicon dioxide as inactive ingredients.

How does Apotex’s excipient list compare with the reference product?

The inactive ingredients in Apotex’s tablets largely match those found in the innovator product. Both use microcrystalline cellulose and lactose monohydrate as fillers, crospovidone as a disintegrant, and magnesium stearate as a lubricant. Minor differences appear only in the grade or supplier of certain excipients rather than in the identity of the materials themselves.

When will the patent on the original ruxolitinib formulation expire?

The composition-of-matter patent for ruxolitinib is listed to expire in 2026, with some formulation patents extending into 2028. Generic entry by Apotex and other manufacturers is therefore expected after those dates, subject to any remaining regulatory or litigation holds.

Why do companies challenge ruxolitinib patents?

Patent challenges focus on the breadth of formulation claims and the timing of generic launch. Companies argue that certain excipient combinations are obvious once the active ingredient is known, seeking earlier market entry while the reference product’s remaining exclusivity is still in force.

Can biosimilars enter before the ruxolitinib patents expire?

Ruxolitinib is a small-molecule drug, so biosimilar pathways do not apply. Generic small-molecule versions can launch only after patent expiry or a successful patent challenge, and any earlier entry would require a court-approved settlement or a final non-infringement ruling.

[1] https://www.drugpatentwatch.com/drug/ruxolitinib
[2] https://www.drugpatentwatch.com/drug/ruxolitinib#excipients